Lupin, Boehringer Ingelheim expand partnership for co-marketing of 2 oral anti-diabetic drugs

11 Jul 2018 Evaluate

Lupin and Boehringer Ingelheim, a German based pharma major, have expanded their partnership with plans to market two new oral anti-diabetics recently approved by the Drugs Controller General of India (DCGI) - Gibtulio Met (Empagliflozin+ Metformin) and Ajaduo (Empagliflozin +Linagliptin). Both these products belong to a novel class of oral anti-diabetic drugs patented in India and will be launched for the first time by an Indian company. The two products will be co-marketed simultaneously by Boehringer Ingelheim and Lupin across India under different brand names.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×